[{"name":"140O - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced\/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial (ID 346)","mode":"playlist","is_cme":false,"info":{"presentation":"140O - Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced\/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial <small>(ID 346)<\/small>","session":"Proffered Paper session 1 <small>(ID 5)<\/small>","presenter":"Jean-Pierre Ayoub<small> (Montreal, Canada)<\/small>","photo":null},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/346_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/breast2020\/5\/v\/346_1p.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/346_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/5\/v\/346_1p-thumbnails.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"7L2406Y02Vk"}